Lyubomir T Vassilev Selected Research

peposertib

1/2022	DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.
1/2021	DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
1/2020	DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia.
1/2020	Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
12/2019	Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lyubomir T Vassilev Research Topics

Disease

37	Neoplasms (Cancer) 01/2023 - 04/2002
5	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2023 - 05/2006
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 11/2005
3	Leukemia 01/2021 - 11/2005
2	Bites and Stings (Sting) 01/2023 - 01/2022
2	Sarcoma (Soft Tissue Sarcoma) 03/2013 - 05/2011
2	Polyploidy 08/2010 - 11/2008
2	Colonic Neoplasms (Colon Cancer) 03/2005 - 10/2003
1	Triple Negative Breast Neoplasms 01/2023
1	Body Weight (Weight, Body) 01/2020
1	Liposarcoma 11/2012
1	Prostatic Neoplasms (Prostate Cancer) 05/2011
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2008
1	Fibrosarcoma 08/2007

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 01/2023 - 11/2005
9	nutlin 3IBA 05/2011 - 11/2005
8	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 12/2019
6	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2022 - 12/2019
5	peposertibIBA 01/2022 - 12/2019
5	Biomarkers (Surrogate Marker)IBA 12/2019 - 10/2003
4	Phosphotransferases (Kinase)IBA 01/2023 - 01/2009
4	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2013 - 10/2003
3	UbiquitinIBA 06/2008 - 05/2003
2	AndrogensIBA 04/2013 - 05/2011
2	RG7112IBA 04/2013 - 11/2012
2	CytokinesIBA 09/2009 - 10/2003
2	RO 3306IBA 11/2008 - 11/2006
2	Cyclin-Dependent Kinase Inhibitor p27IBA 01/2005 - 05/2003
1	InterferonsIBA 01/2023
1	DNA-Activated Protein KinaseIBA 01/2022
1	Topoisomerase II InhibitorsIBA 01/2021
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2021
1	CPX-351IBA 01/2021
1	CalicheamicinsIBA 01/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	Gemtuzumab (Mylotarg)FDA Link 01/2020
1	A-Form DNA (A-DNA)IBA 12/2019
1	Checkpoint Kinase 2IBA 12/2019
1	RO8994IBA 08/2014
1	Peptides (Polypeptides)IBA 09/2013
1	ATSP-7041IBA 09/2013
1	Ifosfamide FDA LinkGeneric 03/2013
1	Cisplatin (Platino)FDA LinkGeneric 05/2011
1	Methotrexate (Mexate)FDA LinkGeneric 05/2011
1	Hormones (Hormone)IBA 05/2011
1	Androgen Receptors (Androgen Receptor)IBA 05/2011
1	TubulinIBA 08/2010
1	NocodazoleIBA 08/2010
1	Calcitriol (Calcijex)FDA LinkGeneric 05/2010
1	pyrimidineIBA 01/2009
1	Ligases (Synthetase)IBA 06/2008
1	LigandsIBA 04/2008
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2008
1	Proto-Oncogene Proteins c-mdm2IBA 05/2007
1	Histone Deacetylase InhibitorsIBA 08/2005
1	trichostatin A (A 300)IBA 08/2005
1	Histone Deacetylases (Histone Deacetylase)IBA 08/2005
1	romidepsin (FK228)FDA Link 08/2005
1	Antimitotic AgentsIBA 03/2005
1	Paclitaxel (Taxol)FDA LinkGeneric 03/2005
1	Cytostatic AgentsIBA 04/2004
1	Culture MediaIBA 10/2003
1	Transforming Growth Factor beta (TGF-beta)IBA 10/2003
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 05/2003
1	Ro 41-4439IBA 04/2002
1	AcidsIBA 04/2002
1	Cytotoxins (Cytolysins)IBA 04/2002

Therapy/Procedure

30	Therapeutics 01/2023 - 10/2003
7	Drug Therapy (Chemotherapy) 01/2023 - 03/2005
5	Radiotherapy 01/2023 - 12/2019
3	Oral Administration 01/2022 - 04/2013
2	Immunotherapy 01/2023 - 01/2022
1	Radioimmunotherapy 01/2022
1	Castration 05/2011
1	Oncolytic Virotherapy 05/2007